Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bracco SPA

www.bracco.com

Latest From Bracco SPA

Increasingly Less-Invasive Diagnostic Techs To Disrupt Interventional Cardio Market

The global market for diagnostic and guided interventional cardiology products is expected to reach $4.8bn by 2021, and is driven in large part by the rising elderly population and increasing burden of cardiovascular disease (CVD). Meddevicetracker expects that intracardiac echocardiography (ICE), guide wire-based intravascular stenosis assessment (FFR) and optical coherence tomography (OCT) systems will drive overall market growth, given their high demand, which is supported by clinical evidence needed to bring cost savings and improved outcomes. Physicians' preference for using noninvasive and minimally invasive diagnostic techniques in cases where results are inconclusive is also changing the landscape of innovation. In this feature, we'll take a closer look at the overall market and its regional perspective, the competitive landscape of the three fastest-growing segments ICE, FFR and OCT, and the latest emerging technologies, as well as provide insight into what physicians think of these technologies.

Cardiology Diagnostics

Scrip 100: The Architecture Of A Top Heavy Industry

Pharmaceutical revenues were down slightly; so was R&D spending, thanks to a strengthening dollar. Scrip analyzes 620 companies and uses numbers, clocks and tiers to paint some data pictures of the pharmaceutical industry in 2015.

Commercial Market Intelligence

Keeping Track: Chugai Delivers Two Breakthroughs For Roche; FDA Continues To Wrestle With Opioid Regulation

The latest drug development news and highlights from our FDA Performance Tracker.

United States BioPharmaceutical

EnteroMedics Appoints CEO

EnteroMedics Inc., a company developing medical devices, has appointed Dan Gladney president and CEO – effective Nov. 16, 2015. Gladney has also been appointed to the company's board. Current president, CEO and chair of EnteroMedics, Mark Knudson, will remain its executive chair until the beginning of 2016, when he will become non-executive chair of the company's board. Most recently Gladney was director and CEO of Lanx Inc., a medical device company, which was later acquired by Biomet Inc. Prior to Lanx, Gladney was healthcare operating partner at Norwest Equity Partners and prior to this, he was president and CEO of various companies including Heart Leaflet Technologies and ACIST Medical Systems, both of which were acquired by The Bracco Group.

Companies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register